5-(benzyloxy)-1,1-dimethoxy-1,2-dihydrocyclobutabenzene | 1222090-71-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5-(benzyloxy)-1,1-dimethoxy-1,2-dihydrocyclobutabenzene
• 英文别名: 8,8-dimethoxy-3-phenylmethoxybicyclo[4.2.0]octa-1(6),2,4-triene
• CAS: 1222090-71-2
• 化学式: C₁₇H₁₈O₃
• 分子量: 270.328
• InChiKey: UIYHTDUQIMKLJY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  27.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-(benzyloxy)-1,1-dimethoxy-1,2-dihydrocyclobutabenzene 在 盐酸 、 potassium tert-butylate 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 3.0h， 生成 5-(benzyloxy)-1-methylene-1,2-dihydrocyclobutabenzene
  参考文献：
  名称：

  Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles

  摘要：

  GPR40 (FFAR1 or FFA1) is a target of high interest being pursued to treat type II diabetes due to its unique Mechanism leading to :little risk of hypoglycemia. We recently reported the discovery of AM-1638 (2), a potent full agonist. GPR40. In this report, we present the discovery Of GPR40 full agonists containing conformationally constrained tricyclic spirocycles and their structure- activity relationships leading to More potent agonists such as AM-5262 (26) with improved rat PK profile and general selectivity profile. AM-5262 enhanced glucose stimulated insulin secretion (mouse and human islets) and improved glucose homeostasis in vivo (OGTT in HF/STZ mice) when compared to AM-1638.,

  DOI：

  10.1021/ml300427u
• 作为产物：
  描述：

  4-苄氧基溴苯 、 1,1-二甲氧基乙烯 在 sodium amide 作用下， 以 四氢呋喃 为溶剂， 反应 48.0h， 以60%的产率得到5-(benzyloxy)-1,1-dimethoxy-1,2-dihydrocyclobutabenzene
  参考文献：
  名称：

  [EN] SPIROCYCLIC GPR40 MODULATORS
  [FR] MODULATEURS SPIROCYCLIQUES DE GPR40

  摘要：

  公开号：

  WO2010045258A3

文献信息

• SPIROCYCLIC GPR40 MODULATORS
  申请人：Brown Sean P.

  公开号：US20110190330A1

  公开（公告）日：2011-08-04

  The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula IA, IB, I′A or I′B: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.

  本发明提供了一些化合物，例如用于治疗受试者的代谢性疾病。这些化合物具有一般式IA、IB、I′A或I′B，其中变量的定义在此处提供。本发明还提供了包括这些化合物的组合物，以及使用这些化合物制备药物和治疗代谢性疾病（例如2型糖尿病）的方法。
• Spirocyclic GPR40 modulators
  申请人：Brown Sean P.

  公开号：US08748462B2

  公开（公告）日：2014-06-10

  The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula IA, IB, I′A or I′B: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.

  本发明提供了一些化合物，例如用于治疗受试者的代谢紊乱。这些化合物具有IA、IB、I’A或I’B的一般公式，其中变量的定义在此处提供。本发明还提供了包括这些化合物的组合物和使用这些化合物制备药物以及治疗代谢性疾病的方法，例如2型糖尿病。
• [EN] SPIROCYCLIC GPR40 MODULATORS<br/>[FR] MODULATEURS SPIROCYCLIQUES DE GPR40
  申请人：AMGEN INC

  公开号：WO2010045258A3

  公开（公告）日：2010-07-01
• US8748462B2
  申请人：——

  公开号：US8748462B2

  公开（公告）日：2014-06-10
• Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles
  作者：Yingcai Wang、Jiwen (Jim) Liu、Paul J. Dransfield、Liusheng Zhu、Zhongyu Wang、Xiaohui Du、Xianyun Jiao、Yongli Su、An-rong Li、Sean P. Brown、Annie Kasparian、Marc Vimolratana、Ming Yu、Vatee Pattaropong、Jonathan B. Houze、Gayathri Swaminath、Thanhvien Tran、Khanh Nguyen、Qi Guo、Jane Zhang、Run Zhuang、Frank Li、Lynn Miao、Michael D. Bartberger、Tiffany L. Correll、David Chow、Simon Wong、Jian Luo、Daniel C.-H. Lin、Julio C. Medina

  DOI：10.1021/ml300427u

  日期：2013.6.13

  GPR40 (FFAR1 or FFA1) is a target of high interest being pursued to treat type II diabetes due to its unique Mechanism leading to :little risk of hypoglycemia. We recently reported the discovery of AM-1638 (2), a potent full agonist. GPR40. In this report, we present the discovery Of GPR40 full agonists containing conformationally constrained tricyclic spirocycles and their structure- activity relationships leading to More potent agonists such as AM-5262 (26) with improved rat PK profile and general selectivity profile. AM-5262 enhanced glucose stimulated insulin secretion (mouse and human islets) and improved glucose homeostasis in vivo (OGTT in HF/STZ mice) when compared to AM-1638.,